Market Closed -
Nasdaq
04:00:00 2024-06-07 pm EDT
|
5-day change
|
1st Jan Change
|
151
USD
|
-2.38%
|
|
+5.93%
|
+51.85%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
6,518
|
41,340
|
102,976
|
69,006
|
37,919
|
57,873
|
-
|
-
|
Enterprise Value (EV)
1 |
5,548
|
36,842
|
92,848
|
59,104
|
29,315
|
51,623
|
53,933
|
54,874
|
P/E ratio
|
-12.6
x
|
-53.3
x
|
8.98
x
|
8.93
x
|
-8.07
x
|
-21.4
x
|
-28.9
x
|
-82.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
108
x
|
51.5
x
|
5.58
x
|
3.58
x
|
5.54
x
|
13.9
x
|
12
x
|
8.92
x
|
EV / Revenue
|
92.1
x
|
45.9
x
|
5.03
x
|
3.07
x
|
4.28
x
|
12.4
x
|
11.1
x
|
8.46
x
|
EV / EBITDA
|
-10.8
x
|
-50.3
x
|
6.86
x
|
6.05
x
|
-8.1
x
|
-18.4
x
|
-25.9
x
|
-79.2
x
|
EV / FCF
|
-11.3
x
|
18.8
x
|
6.96
x
|
12.9
x
|
-7.66
x
|
-19.7
x
|
-27.4
x
|
-44.7
x
|
FCF Yield
|
-8.84%
|
5.32%
|
14.4%
|
7.75%
|
-13%
|
-5.08%
|
-3.66%
|
-2.24%
|
Price to Book
|
6.14
x
|
16.3
x
|
7.24
x
|
3.7
x
|
2.74
x
|
5.18
x
|
6.43
x
|
7.69
x
|
Nbr of stocks (in thousands)
|
333,250
|
395,710
|
405,450
|
384,180
|
381,284
|
383,240
|
-
|
-
|
Reference price
2 |
19.56
|
104.5
|
254.0
|
179.6
|
99.45
|
151.0
|
151.0
|
151.0
|
Announcement Date
|
2/26/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
60.21
|
803.4
|
18,471
|
19,263
|
6,848
|
4,168
|
4,840
|
6,488
|
EBITDA
1 |
-514.7
|
-731.9
|
13,528
|
9,768
|
-3,618
|
-2,800
|
-2,083
|
-692.6
|
EBIT
1 |
-545.7
|
-763.1
|
13,296
|
9,420
|
-4,239
|
-3,032
|
-2,322
|
-988.4
|
Operating Margin
|
-906.38%
|
-94.99%
|
71.98%
|
48.9%
|
-61.9%
|
-72.75%
|
-47.97%
|
-15.24%
|
Earnings before Tax (EBT)
1 |
-514.7
|
-744.5
|
13,285
|
9,575
|
-3,942
|
-2,558
|
-1,955
|
-145.1
|
Net income
1 |
-514
|
-747.1
|
12,202
|
8,362
|
-4,714
|
-2,673
|
-2,039
|
-575.6
|
Net margin
|
-853.73%
|
-92.99%
|
66.06%
|
43.41%
|
-68.84%
|
-64.13%
|
-42.13%
|
-8.87%
|
EPS
2 |
-1.550
|
-1.960
|
28.29
|
20.12
|
-12.33
|
-7.054
|
-5.229
|
-1.822
|
Free Cash Flow
1 |
-490.5
|
1,960
|
13,336
|
4,581
|
-3,825
|
-2,625
|
-1,972
|
-1,227
|
FCF margin
|
-814.7%
|
243.91%
|
72.2%
|
23.78%
|
-55.86%
|
-62.98%
|
-40.74%
|
-18.91%
|
FCF Conversion (EBITDA)
|
-
|
-
|
98.58%
|
46.9%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
109.29%
|
54.78%
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
7,211
|
6,066
|
4,749
|
3,364
|
5,084
|
1,862
|
344
|
1,831
|
2,811
|
167
|
134.4
|
1,516
|
2,350
|
574
|
422.7
|
EBITDA
1 |
5,488
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
208
|
-
|
-1,351
|
-493.4
|
-
|
-
|
-
|
EBIT
1 |
5,410
|
4,227
|
2,447
|
1,166
|
1,580
|
-366
|
-1,867
|
-2,012
|
6
|
-1,266
|
-1,336
|
-532.9
|
97.29
|
-970.8
|
-1,085
|
Operating Margin
|
75.02%
|
69.68%
|
51.53%
|
34.66%
|
31.08%
|
-19.66%
|
-542.73%
|
-109.89%
|
0.21%
|
-758.08%
|
-994.22%
|
-35.14%
|
4.14%
|
-169.13%
|
-256.57%
|
Earnings before Tax (EBT)
1 |
5,410
|
4,229
|
2,474
|
1,217
|
1,655
|
-305
|
-1,749
|
-1,958
|
70
|
-1,165
|
-1,265
|
-455.1
|
252.8
|
-918.2
|
-994.8
|
Net income
1 |
4,868
|
3,657
|
2,197
|
1,043
|
1,465
|
79
|
-1,380
|
-3,630
|
217
|
-1,175
|
-1,293
|
-481.1
|
264.9
|
-918.2
|
-994.8
|
Net margin
|
67.51%
|
60.29%
|
46.26%
|
31%
|
28.82%
|
4.24%
|
-401.16%
|
-198.25%
|
7.72%
|
-703.59%
|
-962.25%
|
-31.73%
|
11.27%
|
-159.97%
|
-235.33%
|
EPS
2 |
11.29
|
8.580
|
5.240
|
2.530
|
3.610
|
0.1900
|
-3.620
|
-9.530
|
0.5500
|
-3.070
|
-3.347
|
-1.210
|
0.5264
|
-2.729
|
-2.810
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/4/22
|
8/3/22
|
11/3/22
|
2/23/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/22/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
971
|
4,498
|
10,128
|
9,902
|
8,604
|
6,250
|
3,940
|
2,999
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-491
|
1,960
|
13,336
|
4,581
|
-3,825
|
-2,625
|
-1,972
|
-1,227
|
ROE (net income / shareholders' equity)
|
-38%
|
-40%
|
146%
|
50.3%
|
-28.6%
|
-22.6%
|
-19.1%
|
-11%
|
ROA (Net income/ Total Assets)
|
-28.9%
|
-16.7%
|
76.2%
|
33.1%
|
-21.3%
|
-15.9%
|
-14.5%
|
-8.37%
|
Assets
1 |
1,776
|
4,463
|
16,003
|
25,264
|
22,142
|
16,786
|
14,109
|
6,879
|
Book Value Per Share
2 |
3.190
|
6.420
|
35.10
|
48.50
|
36.30
|
29.20
|
23.50
|
19.60
|
Cash Flow per Share
2 |
-
|
5.320
|
31.60
|
12.00
|
-8.160
|
-6.940
|
-4.550
|
1.890
|
Capex
1 |
31.6
|
67.4
|
284
|
400
|
707
|
890
|
480
|
520
|
Capex / Sales
|
52.41%
|
8.4%
|
1.54%
|
2.08%
|
10.32%
|
21.36%
|
9.92%
|
8.01%
|
Announcement Date
|
2/26/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Average target price
143.9
USD Spread / Average Target -4.68% Consensus |
1st Jan change
|
Capi.
|
---|
| +51.85% | 57.87B | | +41.42% | 40.25B | | -5.25% | 39.94B | | -5.16% | 28.54B | | +12.79% | 26.4B | | -20.18% | 19.33B | | +30.88% | 12.4B | | +0.61% | 12.23B | | +25.06% | 12.2B | | -9.14% | 11.06B |
Other Biotechnology & Medical Research
|